Presentation Summary

Specifics

Relapsed/Refractory setting: Novel agent naïve patients 

  • BTKi vs PI3Ki vs. Venetoclax as first novel agent?   
    • In all circumstances, when clinically acceptable, the data support BTKi or Ven before approved PI3Ki. 
    • No definitive comparative data to support Ven vs. BTKi as first novel agent in novel agent naïve R/R CLL, but limited RWE data is intriguing. 

But which BTKi in R/R disease? 

  • Ibrutinib vs. Acalabrutinib  
  • Ibrutinib vs. Zanubrutinib